A Phase 2 interventional study of Lidocaine and Botulinum toxin type A in Chronic Scar Pain, sponsored by Ipsen. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-12.
Sponsored by Ipsen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing botulinum toxin type A in Cicatrix — 1 open to participants now, 2 under way, none of them phase 3. botulinum toxin type A · Cicatrix.
Among the 12 studies testing botulinum toxin type A in Cicatrix, this one is the 10th largest by enrollment, is the only one that started in 2018, is one of 3 in phase 2, and was the 7th registered.
613 studies on the registry are indexed under Cicatrix; 115 are open to participants now.
Browse Cicatrix studies →1 of the 12 studies testing botulinum toxin type A in Cicatrix is open now, in 1 country. Recruiting first, the newest first:
University of Sao Paulo · Sites in Brazil
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 3 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 513 interventional studies indexed under Cicatrix.
Median enrollment 36 across the 12 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 1 study filed under Cicatrix — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing botulinum toxin type A in Cicatrix, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is designed to determine whether a currently licensed version of botulinum toxin (Dysport®) is effective for the treatment of pain that has developed and/or persisted for months or years around the scar of a previous surgical site, and whether this condition could be suitable for the testing of similar new medicines. The study will compare three different doses of Dysport® to see if there is benefit and/or a best dose for treating persistent post-surgery scar pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Crossover run-in part A - Subjects will be injected (Test 1) with either saline or local anaesthetic (lidocaine). One week later, they will be crossed over, injected with the other agent (Test 2).
Drug: Lidocaine · Drug: Placebo
Dysport dose 1 as a single-dose, intradermal injection.
Biological: Botulinum toxin type A
Dysport dose 2 as a single-dose, intradermal injection.
Biological: Botulinum toxin type A
Dysport dose 3 as a single-dose, intradermal injection.
Biological: Botulinum toxin type A
Placebo single-dose, intradermal injection.
Drug: Placebo
0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
Also known as: AbobotulinumtoxinA (Dysport®)
Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
Also known as: Saline solution
Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
Time to Onset of Effect in the Spontaneous Numerical Rating Scale (NRS) Score
The time to onset of effect was defined as the time to a decrease from baseline of two points or greater in the spontaneous NRS score. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Only descriptive statistical analysis was performed for this outcome measure.
Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Peak Effect in the Spontaneous NRS Score
The peak effect was defined as the maximal decrease from baseline in the spontaneous NRS score over a 12-hour period. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Greater reductions in change from baseline correspond to greater pain relief.
Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Time to Peak Effect in the Spontaneous NRS Score
The time to peak effect was defined as the time to reach the peak effect over a 12-hour period. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours."
Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Duration of Effect in the Spontaneous NRS Score
The duration of effect was defined as the duration between time to onset and last timepoint for which decrease from baseline in the spontaneous NRS score was two points or greater. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours."
Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Change From Baseline in the Spontaneous NRS Score Throughout the Study
Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Greater reductions in change from baseline correspond to greater pain relief.
Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Change From Baseline in the Stimulus-Evoked NRS Score on the Painful Area at Weeks 6 and 12
For stimulus-evoked NRS score during Quantitative Sensory Testing, participants were submitted to stimuli of various nature (light touch, pressure and temperature) applied to the painful area. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Static mechanical allodynia is the response to light sustained normally innocuous pressure against the skin. Dynamic mechanical allodynia is the response to a normally innocuous light moving mechanical stimulus on the skin. Temporal summation is a condition, which demonstrates an increased perception of pain to repetitive painful stimuli.
Time frame: Part B: Baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) and Weeks 6 and 12
This Phase II proof-of-concept study was conducted at single investigational site in the United Kingdom between 30 October 2018 and 08 November 2019. The study consisted of two sequential parts: Part A (Pre-randomisation run-in period) and Part B (Randomised double-blind period). Part A was considered as an extended screening period.
| Milestone | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site |
|---|---|---|---|---|
| Started | 4 | 3 | 5 | 4 |
| Completed | 4 | 3 | 5 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
The time to onset of effect was defined as the time to a decrease from baseline of two points or greater in the spontaneous NRS score. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Only descriptive statistical analysis was performed for this outcome measure.
| days | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site |
|---|---|---|---|---|
| Worst NRS score | 4.41 ± 4.92 | 15.11 ± 25.17 | 29.45 ± 39.82 | 0.65 ± 0.32 |
| Average NRS score | 6.75 ± 2.74 | 31.63 ± 53.78 | 4.60 ± 6.55 | 0.90 ± 0.03 |
The peak effect was defined as the maximal decrease from baseline in the spontaneous NRS score over a 12-hour period. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Greater reductions in change from baseline correspond to greater pain relief.
| score on a scale | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site |
|---|---|---|---|---|
| Worst NRS score | -2.36 ± 1.58 | -4.73 ± 0.55 | -3.54 ± 2.15 | -2.82 ± 2.91 |
| Average NRS score | -2.52 ± 0.91 | -3.53 ± 0.45 | -3.72 ± 1.57 | -2.12 ± 2.37 |
The time to peak effect was defined as the time to reach the peak effect over a 12-hour period. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours."
| days | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site |
|---|---|---|---|---|
| Worst NRS score | 10.63 ± 10.18 | 33.46 ± 51.41 | 41.94 ± 35.72 | 3.11 ± 1.56 |
| Average NRS score | 12.51 ± 7.26 | 33.13 ± 52.51 | 11.04 ± 11.58 | 26.49 ± 49.89 |
The duration of effect was defined as the duration between time to onset and last timepoint for which decrease from baseline in the spontaneous NRS score was two points or greater. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours."
| days | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site |
|---|---|---|---|---|
| Worst NRS score | 86.04 ± 25.52 | 86.68 ± 23.89 | 66.80 ± 44.28 | 110.52 ± 0.74 |
| Average NRS score | 53.53 ± 51.44 | 65.17 ± 58.21 | 102.75 ± 18.36 | 110.02 ± 1.45 |
Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Greater reductions in change from baseline correspond to greater pain relief.
| score on a scale | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site |
|---|---|---|---|---|
| Daily worst NRS score: Baseline | 5.1 ± 1.0 | 5.1 ± 1.0 | 5.3 ± 1.6 | 5.8 ± 0.9 |
| Daily worst NRS score: Week 2 | -0.6 ± 0.9 | -2.1 ± 2.1 | -1.4 ± 3.5 | -1.1 ± 2.7 |
| Daily worst NRS score: Week 4 | -1.6 ± 1.8 | -2.1 ± 1.8 | -1.4 ± 4.2 | -1.6 ± 2.7 |
| Daily worst NRS score: Week 6 | -1.1 ± 0.7 | -0.1 ± 1.0 | -1.7 ± 2.9 | -1.6 ± 2.6 |
| Daily worst NRS score: Week 12 | -0.5 ± 1.4 | -1.4 ± 0.6 | -0.7 ± 1.1 | -0.8 ± 3.3 |
| Daily worst NRS score: Week 16 | -0.0 ± 2.0 | -1.4 ± 1.1 | -1.3 ± 3.1 | -0.3 ± 1.7 |
| Daily average NRS score: Baseline | 4.5 ± 1.1 | 3.9 ± 1.0 | 4.7 ± 1.2 | 4.9 ± 1.2 |
| Daily average NRS score: Week 2 | -0.9 ± 1.0 | -2.0 ± 1.8 | -2.1 ± 2.8 | -1.7 ± 2.5 |
| Daily average NRS score: Week 4 | -1.6 ± 1.9 | -1.9 ± 1.3 | -2.1 ± 3.2 | -1.4 ± 2.0 |
| Daily average NRS score: Week 6 | -1.0 ± 0.9 | -0.4 ± 2.0 | -2.0 ± 2.6 | -1.4 ± 2.0 |
| Daily average NRS score: Week 12 | -0.5 ± 1.6 | -1.5 ± 0.6 | -1.2 ± 1.9 | -0.6 ± 2.5 |
| Daily average NRS score: Week 16 | -0.6 ± 1.5 | -0.9 ± 0.8 | -1.6 ± 2.3 | -0.4 ± 1.5 |
For stimulus-evoked NRS score during Quantitative Sensory Testing, participants were submitted to stimuli of various nature (light touch, pressure and temperature) applied to the painful area. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Static mechanical allodynia is the response to light sustained normally innocuous pressure against the skin. Dynamic mechanical allodynia is the response to a normally innocuous light moving mechanical stimulus on the skin. Temporal summation is a condition, which demonstrates an increased perception of pain to repetitive painful stimuli.
| score on a scale | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site |
|---|---|---|---|---|
| Static mechanical allodynia: Baseline | 1.3 ± 1.5 | 3.0 ± 3.6 | 4.2 ± 1.1 | 4.5 ± 3.1 |
| Static mechanical allodynia: Week 6 | 1.0 ± 1.2 | -1.7 ± 4.0 | -2.6 ± 1.8 | -1.0 ± 5.5 |
| Static mechanical allodynia: Week 12 | 0.8 ± 1.0 | -0.3 ± 5.7 | -2.0 ± 1.4 | -0.8 ± 5.1 |
| Dynamic mechanical allodynia: Baseline | 1.3 ± 1.0 | 2.3 ± 3.2 | 2.4 ± 1.7 | 5.3 ± 1.0 |
| Dynamic mechanical allodynia: Week 6 | -0.5 ± 1.0 | -1.7 ± 2.1 | -2.0 ± 1.9 | -2.5 ± 2.6 |
| Dynamic mechanical allodynia: Week 12 | -0.3 ± 2.1 | -1.3 ± 1.5 | -0.2 ± 1.5 | -2.0 ± 2.7 |
| Temporal summation: Baseline | 1.5 ± 1.3 | 0.3 ± 1.5 | 3.6 ± 3.0 | 1.8 ± 2.1 |
| Temporal summation: Week 6 | 1.8 ± 2.1 | 0.3 ± 0.6 | 1.8 ± 1.1 | 2.8 ± 1.7 |
| Temporal summation: Week 12 | 2.0 ± 0.8 | 0.3 ± 3.1 | 1.4 ± 1.1 | 2.8 ± 1.7 |
Collected over Treatment-emergent adverse events were collected from the start of study drug administration (Day 1) in Part B up to end of study visit or early discontinuation, approximately 16 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Dysport 2.5 U/Injection Site | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Dysport 10 U/Injection Site | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Dysport 20 U/Injection Site | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site |
|---|---|---|---|---|
| Pancreatogenous diabetesMetabolism and nutrition disorders | 0/4 | 1/3 | 0/5 | 0/4 |
| Event | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/4 | 0/3 | 2/5 | 3/4 |
| NasopharyngitisInfections and infestations | 2/4 | 0/3 | 2/5 | 0/4 |
| DizzinessNervous system disorders | 0/4 | 1/3 | 1/5 | 1/4 |
| ParaesthesiaNervous system disorders | 0/4 | 1/3 | 0/5 | 0/4 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 1/3 | 1/5 | 0/4 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/4 | 1/3 | 0/5 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 1/3 | 0/5 | 0/4 |
| VomitingGastrointestinal disorders | 0/4 | 1/3 | 0/5 | 1/4 |
| Abdominal painGastrointestinal disorders | 0/4 | 1/3 | 0/5 | 0/4 |
| Gastric mucosa erythemaGastrointestinal disorders | 0/4 | 1/3 | 0/5 | 0/4 |
Randomised population included all participants randomised in the double-blind period (Part B).
| Age, Continuous(years) | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site | Total |
|---|---|---|---|---|---|
| Mean | 56.5 ± 10.7 | 49.7 ± 6.0 | 46.0 ± 11.3 | 48.8 ± 16.7 | 50.0 ± 11.6 |
| Sex: Female, Male(Participants) | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site | Total |
|---|---|---|---|---|---|
| Female | 3 | 3 | 3 | 2 | 11 |
| Male | 1 | 0 | 2 | 2 | 5 |
| Race (NIH/OMB)(Participants) | Placebo | Dysport 2.5 U/Injection Site | Dysport 10 U/Injection Site | Dysport 20 U/Injection Site | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 3 | 2 | 3 | 12 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Nov 2019, 12 months.
Results were first posted in Dec 2020, 1 year after primary completion.
Of 24 phase 2 interventional studies under Cicatrix, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 61. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lidocaine · Botulinum toxin type A